Want to see GB:OBD full AI Analyst Report?
Top Page
Oxford BioDynamics
(LSE:OBD)
Select Model
Select Model
Rating:42Neutral
Price Target:
0.11 p
▼(-11.67% Downside)
Action:Reiterated
Date:07/29/26
The score is held down primarily by weak financial performance (ongoing losses, high leverage, and pressured cash flow). Technicals are also unfavorable overall, with price below longer-term moving averages despite being above the 20-day average. Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Revenue Growth
Positive revenue growth indicates increasing commercial activity and demand for Oxford BioDynamics’ offerings. If sustained, it can improve operating leverage and support broader adoption of its diagnostic tests and platform partnerships.
Negative Factors
Persistent Unprofitability
Ongoing losses and negative operating margins show that revenue has not yet translated into sustainable profitability. Continued cost pressure could limit reinvestment capacity and increase dependence on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Positive revenue growth indicates increasing commercial activity and demand for Oxford BioDynamics’ offerings. If sustained, it can improve operating leverage and support broader adoption of its diagnostic tests and platform partnerships.
Read all positive factors
Oxford BioDynamics (OBD) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£15.79M
Dividend YieldN/A
Average Volume (3M)21.87M
Price to Earnings (P/E)―
Beta (1Y)-0.56
Revenue Growth33.37%
EPS Growth86.41%
CountryUK
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding13,440,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£1.80M
Oxford BioDynamics Business Overview & Revenue Model
Company Description
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering ...
How the Company Makes Money
OBD’s monetization is centered on commercializing tests and licensing/partnering its EpiSwitch platform. Key revenue streams include: (1) Sales of diagnostic tests and related services: revenue generated from providing EpiSwitch-based blood tests ...
Oxford BioDynamics Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
25
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.20M | 1.09M | 636.00K | 510.00K | 154.00K | 341.00K |
| Gross Profit | -3.31M | -6.15M | 289.00K | 266.00K | 116.00K | -557.00K |
| EBITDA | -8.89M | -9.80M | -10.27M | -9.84M | -6.16M | -6.43M |
| Net Income | -9.87M | -11.15M | -11.57M | -10.83M | -6.71M | -6.68M |
Balance Sheet | ||||||
| Total Assets | 9.09M | 8.09M | 12.11M | 16.13M | 11.34M | 15.38M |
| Cash, Cash Equivalents and Short-Term Investments | 2.51M | 1.39M | 2.83M | 5.25M | 999.00K | 4.34M |
| Total Debt | 4.28M | 5.11M | 5.74M | 6.44M | 6.14M | 6.59M |
| Total Liabilities | 5.84M | 6.97M | 7.75M | 10.07M | 8.76M | 8.69M |
| Stockholders Equity | 3.25M | 1.12M | 4.36M | 6.05M | 2.59M | 6.68M |
Cash Flow | ||||||
| Free Cash Flow | -7.30M | -7.73M | -10.77M | -9.01M | -6.08M | -9.01M |
| Operating Cash Flow | -7.28M | -7.71M | -10.17M | -8.29M | -5.18M | -5.92M |
| Investing Cash Flow | -117.00K | 756.00K | -1.49M | -691.00K | 1.25M | 2.83M |
| Financing Cash Flow | 5.65M | 6.52M | 8.25M | 13.42M | 2.56M | -804.00K |
Oxford BioDynamics Technical Analysis
Negative
0.12
Price Trends
0.12
Negative
0.16
Negative
0.21
Negative
Market Momentum
>-0.01
Negative
48.15
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.
Oxford BioDynamics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £16.97M | -3.95 | -16.18% | ― | 13.04% | 15.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £24.62M | -52.78 | -5.25% | ― | 95.16% | 85.60% | |
44 Neutral | £13.14M | -8.68 | -210.32% | ― | -11.43% | 23.40% | |
44 Neutral | £11.89M | -6.03 | 332.06% | ― | ― | 29.79% | |
42 Neutral | £15.79M | -0.30 | -451.74% | ― | 33.37% | 86.41% | |
40 Underperform | £11.27M | -3.25 | -135.35% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:OBD
Oxford BioDynamics
0.12
-0.36
-75.00%
GB:IXI
IXICO plc
7.75
-4.50
-36.73%
GB:SBTX
SkinBioTherapeutics
9.50
-4.75
-33.33%
GB:FAB
Fusion Antibodies Plc
12.50
-2.25
-15.25%
GB:GENF
Genflow Biosciences Plc
2.05
1.30
173.33%
GB:APTA
Aptamer Group Plc
0.33
-0.88
-72.92%
Oxford BioDynamics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Oxford BioDynamics strengthens board with CEO Richard Compton appointment
Positive
Aug 27, 2026
Oxford BioDynamics has strengthened its leadership structure with the appointment of Chief Executive Officer Richard Compton to its board as an executive director, following completion of regulatory due diligence. The move further aligns managemen...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
Oxford BioDynamics Wins Shareholder Backing for Massive AIM Placing
Positive
Aug 26, 2026
Oxford BioDynamics has confirmed that shareholders approved all resolutions at its General Meeting related to a previously announced placing. The biotech group, which develops personalised diagnostic tests and operates its EpiSwitch Orion 3D genom...
Business Operations and StrategyProduct-Related Announcements
Oxford BioDynamics strikes first Gulf deal for prostate cancer test with Dubai London Clinics
Positive
Aug 13, 2026
Oxford BioDynamics has signed a partnership with The Dubai London Clinics Hospitals Group to make its EpiSwitch PSE prostate cancer blood test available across DLCH’s network in the United Arab Emirates. Under the agreement, blood samples w...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Oxford BioDynamics seeks £9.15m lifeline in discounted AIM share placing
Negative
Aug 10, 2026
Oxford BioDynamics has launched a deeply discounted placing of 9.15 billion new shares at £0.001 per share to raise £9.15 million, alongside issuing broker warrants, with the new equity representing around 68.1% of the enlarged share cap...
Business Operations and StrategyProduct-Related Announcements
Oxford BioDynamics lands first paid deal for EpiSwitch Orion in UK psoriatic arthritis study
Positive
Jul 28, 2026
Oxford BioDynamics has signed its first commercial agreement for EpiSwitch Orion, its cloud-based 3D genomics discovery platform, marking the first paid third-party access to the system. The deal sits within OPTIMISE, a UK government-funded transl...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Oxford BioDynamics boosts test sales and launches Orion but faces funding deadline
Neutral
Jun 30, 2026
Oxford BioDynamics reported interim results showing modest revenue growth to £0.69m and a narrowed operating loss of £4.68m, supported by a £6.32m equity raise that lifted period-end cash to £2.51m. However, the board acknowled...
Business Operations and StrategyProduct-Related Announcements
Oxford BioDynamics expands U.S. reach with MK Commercial Group sales partnership
Positive
Jun 30, 2026
Oxford BioDynamics has entered a commercial services agreement with specialist life sciences firm MK Commercial Group to expand its U.S. sales footprint for EpiSwitch PSE, its prostate cancer diagnostic test. The partnership initially deploys seve...
Business Operations and StrategyExecutive/Board Changes
Oxford BioDynamics names genomics veteran Richard Compton as new CEO
Positive
Jun 30, 2026
Oxford BioDynamics has appointed Richard Compton as chief executive officer with immediate effect, with Iain Ross moving from executive to non-executive chairman. Compton, a veteran life sciences executive with senior commercial roles at Oxford Na...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.